Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies)
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cardiovascular disease, the most common cause of death with a functioning graft among kidney transplant recipients, can be exacerbated by immunosuppressive drugs, particularly the calcineurin inhibitors. Belatacept, a selective co-stimulation blocker, may provide a better cardiovascular/metabolic risk profile than current immunosuppressants. METHODS: Cardiovascular and metabolic endpoints from two Phase III studies (BENEFIT and BENEFIT-EXT) of belatacept-based regimens in kidney transplant recipients were assessed at month 12. Each study assessed belatacept in more intensive (MI) and less intensive (LI) regimens versus cyclosporine A (CsA). These secondary endpoints included changes in blood pressure, changes in serum lipids, and the incidence of new-onset diabetes after transplant (NODAT). RESULTS: A total of 1209 patients were randomized and transplanted across the two studies. Mean systolic blood pressure was 6 to 9 mm Hg lower and mean diastolic blood pressure was 3 to 4 mm Hg lower in the MI and LI groups versus CsA (P ≤ 0.002) across both studies at month 12. Non-HDL cholesterol was lower in the belatacept groups versus CsA (P<0.01 MI or LI vs. CsA in each study). Serum triglycerides were lower in the belatacept groups versus CsA (P<0.02 MI or LI vs. CsA in each study). NODAT occurred less often in the belatacept groups versus CsA in a prespecified pooled analysis (P<0.05 MI or LI vs. CsA). CONCLUSIONS: At month 12, belatacept regimens were associated with better cardiovascular and metabolic risk profiles, with lower blood pressure and serum lipids and less NODAT versus CsA. The overall profile of belatacept will continue to be assessed over the 3-year trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An additional consideration is that men with CMD, whether characterized by prediabetes, metabolic syndrome, obesity, or T2D, are at increased risk of hypogonadism and testosterone deficiency.1566–1569”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1569]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 1×
“Reductions of only approximately 3 mm Hg in systolic and diastolic blood pressure are associated with fewer myocardial infarctions and strokes in patients at high risk for cardiovascular events (43).”
BackgroundDiabetes Mellitus after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D., & Matas, A. J. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00010.x · Cited by 1,285
Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R., & Brancati, F. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421301 · Cited by 1,202
Pirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Self-citationVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957
Self-citationManjunath, G., Tighiouart, H., Ibrahim, H., MacLeod, B., Salem, D. N., Griffith, J. L., Coresh, J., Levey, A. S., & Sarnak, M. J. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02663-3 · Cited by 920
Research works printed but not linked: 1
- 2003, Introduction, assessment of dyslipidemias, treating dyslipidemias, and research recommendations., Am J Kidney Dis, 41, S11
Cited by
Items 101–181 of 181
Belatacept: a novel immunosuppressive agent for kidney transplant recipients
Charpentier, B. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.79 · Cited by 12
B7-H4 Pathway in Islet Transplantation andβ-Cell Replacement Therapies
Wang, X., Hao, J., Metzger, D. L., Ao, Z., Meloche, M. R., Verchere, C. B., Chen, L., Ou, D., Mui, A., & Warnock, G. L. (2011) · Journal of Transplantation · doi:10.1155/2011/418902 · Cited by 12
Prediction of Cardiovascular Events After Renal Transplantation
Seibert, F. S., Behrendt, C., Pagonas, N., Bauer, F., Kiziler, F., Zidek, W., & Westhoff, T. H. (2015) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.12.014 · Cited by 13
Klangjareonchai, T., Eguchi, N., Tantisattamo, E., Ferrey, A., Reddy, U. G., Dafoe, D. C., & Ichii, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030413 · Cited by 12
Pérez‐Sáez, M. J., Yu, B., Uffing, A., Murakami, N., Borges, T. J., Azzi, J. R., Haji, S. E., Gabardi, S., & Riella, L. V. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy115 · Cited by 12
New Perspectives of Immunosuppression
Halleck, F., Friedersdorff, F., Fuller, T. F., Matz, M., Huber, L., Dürr, M., Schütz, M., & Budde, K. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.02.033 · Cited by 11
Bredewold, O. W., Chan, J., Svensson, M., Bruchfeld, A. N., de Fijter, J. W., Furuland, H., Grinyo, J. M., Hartmann, A., Holdaas, H., Hellberg, O., et al. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100574 · Cited by 11
Ten Years Experience With Belatacept-Based Immunosuppression After Kidney Transplantation
Grannas, G. (2014) · Journal of Clinical Medicine Research · doi:10.14740/jocmr1697w · Cited by 9
Bertrand, D., Chavarot, N., Olagne, J., Grèze, C., Gatault, P., Danthu, C., Colosio, C., Jaureguy, M., Duveau, A., Bouvier, N., et al. (2024) · Transplant International · doi:10.3389/ti.2024.13544 · Cited by 9
Improving long-term outcomes of kidney transplantation: The pressure is on.
Hesselink, D. A., & Hoorn, E. J. (2014) · PubMed · Cited by 9
New Immunosuppressants in Pediatric Kidney Transplantation: What's in the Pipeline for Kids?
Tönshoff, B., Patry, C., Fichtner, A., Höcker, B., & Böhmig, G. A. (2024) · Pediatric Transplantation · doi:10.1111/petr.70008 · Cited by 8
Heemann, U. W., & Viklický, O. (2012) · Clinical Transplantation · doi:10.1111/ctr.12044 · Cited by 8
Alemtuzumab induction therapy in kidney transplantation
Kuypers, D. R. J. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61174-0 · Cited by 8
New immunosuppressants in pediatric solid organ transplantation
Marks, S. D. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32835741cd · Cited by 8
Paccagnella, C., Andreola, S., Gambaro, A., Gambaro, G., & Caletti, C. (2025) · Cardiorenal Medicine · doi:10.1159/000542378 · Cited by 7
One-Year Outcomes After Belatacept Conversion in Adolescent Kidney Transplant Recipients
Duneton, C., George, R. P., Liverman, R., Sellier‐Leclerc, A., Beauval, B., Baudouin, V., Cheyssac, É., Warshaw, B. L., Hogan, J., & Garro, R. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.03.016 · Cited by 7
Future prospects in immunosuppression for liver transplantation
Fung, J. J., Bollinger, J. E., Miller, C. M., & Eghtesad, B. (2011) · Liver Transplantation · doi:10.1002/lt.22412 · Cited by 7
Belatacept: In Adult Kidney Transplant Recipients
Garnock-Jones, K. P. (2012) · BioDrugs · doi:10.1007/bf03261898 · Cited by 7
De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
Schenk, A. D., Anderson, D. J., Cole, R. T., Badell, I. R., & Larsen, C. P. (2019) · Transplantation Direct · doi:10.1097/txd.0000000000000967 · Cited by 7
Self-citationThe proliferation of belatacept-resistant T cells requires early IFNα pathway activation
Herr, F., Desterke, C., Bargiel, K., Vernochet, A., Vanhove, B., Vadanici, R., Ye, F., Dekeyser, M., & Dürrbach, A. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16811 · Cited by 7
Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients
Bello, A. D., Marion, O., Milongo, D., Rostaing, L. P. E., & Kamar, N. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1112736 · Cited by 8
Recent advances in immunosuppression and acquired immune tolerance in renal transplants
Casiraghi, F., Cortinovis, M., Perico, N., & Remuzzi, G. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00312.2015 · Cited by 7
Long, J., Zhao, J., Gu, X., & Huang, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1829579 · Cited by 6
HOW TO IDENTIFY AND MANAGE DIABETES MELLITUS AFTER RENAL TRANSPLANTATION
Stevens, K. K., Patel, R. K., & Jardine, A. G. (2012) · Journal of Renal Care · doi:10.1111/j.1755-6686.2012.00282.x · Cited by 6
Posttransplantationsdiabetes mellitus: Eine Herausforderung für die Nachsorge
Albersmeyer, M., Gehr, B., Liebl, A., & Gerbig, D. (2020) · Der Nephrologe · doi:10.1007/s11560-020-00436-4 · Cited by 6
Gouin, A., Sberro‐Soussan, R., Courivaud, C., Bertrand, D., Bello, A. D., Darres, A., Ducloux, D., Legendre, C. M., & Kamar, N. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.09.036 · Cited by 6
Belatacept-based immunosuppression in heart transplant recipients: A single center experience
Magua, W., Wang, M., Pobee, D. D., Morris, A. B., Okoh, A. K., Eichenberger, E. M., Karadkhele, G. M., Gupta, D., Vega, J. D., Larsen, C. P., et al. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100277 · Cited by 5
Self-citationMaria, S. D., & Provenzani, A. (2026) · Pharmaceuticals · doi:10.3390/ph19020196 · Cited by 5
Preventing and managing hyperglycemia in kidney transplant patients
Sharif, A. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328358d5d0 · Cited by 5
Luo, B., Zhong, S., Wang, X., Guo, P., Hou, Y., & Di, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1440875 · Cited by 4
A safety evaluation of belatacept for the treatment of kidney transplant
García, V. D., Meinerz, G., & Keitel, E. E. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1202236 · Cited by 4
Herr, F., Dekeyser, M., Pavec, J. L., Desterke, C., Chiron, A., Bargiel, K., Mercier, O. M., Vernochet, A., Fadel, É., & Dürrbach, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041299 · Cited by 4
Bredewold, O. W., van Oeveren‐Rietdijk, A. M., Florijn, B. W., Rotmans, J. I., de Fijter, J. W., van Kooten, C., van Zonneveld, A. J., & de Boer, H. C. (2024) · Transplant Immunology · doi:10.1016/j.trim.2023.101976 · Cited by 3
Formica, R. N., Larsen, C. P., & Rostaing, L. P. E. (2025) · Transplantation · doi:10.1097/tp.0000000000005506 · Cited by 3
Self-citationTreating posttransplantation diabetes mellitus
Pérez‐Sáez, M. J., Marín-Casino, M., & Pascual, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1039983 · Cited by 3
Conclusions et perspectives en transplantation rénale pédiatrique
Roussey‐Kesler, G., & Decramer, S. (2011) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2011.11.008 · Cited by 3
Immunosuppressive agents in diabetes treatment: Hope or despair?
Li, L., Yang, X., Ren, J.-S., Huang, M., & Zhao, Q. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i5.100590 · Cited by 3
wang, X., Song, D., Hou, S., Liu, A., Gao, J., & Liu, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1615875 · Cited by 2
Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma
van Gelder, T., Baan, C. C., Vincenti, F. G., & Mannon, R. B. (2013) · Transplant International · doi:10.1111/tri.12140 · Cited by 2
Self-citationPolyclonal and monoclonal antibodies in renal transplant: an update
Ilahe, A., Budhiraja, P., & Kaplan, B. E. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000171 · Cited by 3
Chronic Kidney Disease in the Kidney Transplant Recipient
Gill, J. S., Mawad, H., & Johnston, O. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00044-6 · Cited by 3
Inhibition of CD154:CD11b interactions using a novel nanotherapeutic improves allograft survival
Yao, H., Bahn-Humphrey, A., Liu, D., Zhu, L., Yang, L., & Ford, M. L. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.01.024 · Cited by 1
New Onset Diabetes After Solid Organ Transplantation
Phuong-Thu, T., Phuong-Mai, T., Parikh, S., Son, V., Phuong-Anh, T., & Phuong-Chi, T. (2011) · InTech eBooks · doi:10.5772/20942 · Cited by 1
Recent advances in immunosuppression for kidney transplantation
Shawky, N. M., Arbagy, A. R. E., Kora, M. A., & Barbary, H. E. (2015) · Menoufia Medical Journal · doi:10.4103/1110-2098.163862 · Cited by 1
Belatacept in renal transplantation—quo vadis?
Westhoff, T. H. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.11.11 · Cited by 1
Belatacept Adult Kidney Transplant Recipients
Garnock-Jones, K. P. (2012) · Cited by 1
Hypertension after Kidney Transplantation
Masin‐Spasovska, J., Stojceva-Taneva, O., Taneva, B., & Spasovski, G. B. (2015) · Macedonian Medical Review · doi:10.1515/mmr-2015-0001 · Cited by 1
Cardiovascular Disease in Renal Transplantation
Lees, J. S., & Jardine, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00030-9 · Cited by 1
Cardiovascular Disease in Renal Transplantation
McQuarrie, E. P., & Jardine, A. G. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4096-3.00030-1 · Cited by 1
Transplantation: Kidney, Kidney–Pancreas Transplant
Zhang, R., & Paramesh, A. S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0793-9_15 · Cited by 1
Influence of Belatacept- vs. CNI-Based Immunosuppression on Vascular Stiffness and Body Composition
Heleniak, Z., Illersperger, S., Naik, M. G., Osmanodja, B., Ronicke, S., Eleftheriadis, G. K., Halleck, F., & Budde, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051219 · Cited by 1
Галеев, Ш. Р., & Gautier, S. V. (2022) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2022-4-24-38 · Cited by 1
Nerve Allograft Transplantation
Sönmez, E., & Siemionow, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6335-0_68
Cardiovascular Disease and Preventive Healthcare after Organ Transplantation
Pastan, S. O., & Gupta, D. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch88
Long‐term Outcomes after Kidney Transplantation
Lodhi, S. A., & Stephens, N. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch103
Comparative Effectiveness in Transplantation
Meister, E. A., & Kaplan, B. E. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch135
Metabolic and Endocrine Management of the Organ Transplant Recipient
Issa, N. S., Reule, S. A., & Kukla, A. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch100
Kidney transplantation: into the future with belatacept
Dürrbach, A., Jacquet, A., François, H., & Charpentier, B. (2012) · Clinical Investigation · doi:10.4155/cli.12.125
Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2
Wojciechowski, D., & Vincenti, F. G. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.09.004
Self-citationThe Role of Human Leukocyte Antigen-G in Cardiac Allograft Vasculopathy
Mociornita, A. G. (2013) · TSpace (University of Toronto)
Sadozai, H. (2016) · TSpace (University of Toronto)
Maintenance Immunosuppression in Kidney Transplantation
Cortinovis, M., Remuzzi, G., & Perico, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00020-5
The multidimensional kidney transplant self-management scale : development and psychometric testing
Chung, S.-Y. (2018) · IUScholarWorks (Indiana University) · doi:10.7912/c24m2n
End Stage Renal Disease – Treatment Options: Dialysis Versus Transplant
Parajuli, S., & Reville, P. K. (2018) · Springer eBooks · doi:10.1007/978-3-030-00132-2_2
Post Kidney Transplant: Cardiovascular Complications
AbdulRahim, N., Tanrıöver, B., & Ariyamuthu, V. K. (2018) · Springer eBooks · doi:10.1007/978-3-030-00132-2_6
Mineral and Bone Disorders Following Renal Transplantation
Amer, H., & Kumar, R. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_18
Future of Solid Organ Transplantation: Organ-Specific Tolerance
Sönmez, Y. E. (2021) · KIDNEYS · doi:10.22141/2307-1257.10.3.2021.239589
Taler, S. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00036-0
Management of new onset dysglycemia in transplant recipients
Sharif, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00045-1
Holdaas, H., KOBASHIGAWA, J. A., Fellström, B., & Jardine, A. G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00040-2
Brinas, F. (2024) · theses.fr (ABES) · doi:10.70675/ff9cb0e5z5757z47c1zb7e5zd851c17109c2
Belatacept in kidney transplantation: balancing the scales
(2025) · Frontiers Media SA eBooks · doi:10.3389/978-2-8325-5922-2
Mogallapalli, H., Osman, F., Parajuli, S., Garg, N., Aziz, F., Djamali, A., Astor, B. C., & Mohamed, M. (2025) · Transplantation Proceedings · doi:10.1016/j.transproceed.2025.03.023
Transplantasyonda Tolerans Oluşturma Stratejileri ve İmmün Mekanizmalar
Tuygun, Ş., & Taş, S. K. (2025) · Journal of Immunology and Clinical Microbiology · doi:10.58854/jicm.1537863
Evaluation and Management of Transplant-Associated Hyperglycemia
Bloom, R. D., & Moussallem, C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0342-9_21
Blumberg, E. A., Gill, J., & Mannon, R. B. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.03.032
Cooper, J. T., & Schneider, J. E. (2026) · Journal of health economics and outcomes research · doi:10.36469/001c.146282
Bredewold, O. W., Postma, R. J., Chan, J., Svensson, M. H. S., Bruchfeld, A. N., de Fijter, J. W., Furuland, H., Hartmann, A., Mjörnstedt, L., Skov, K., et al. (2026) · Frontiers in Transplantation · doi:10.3389/frtra.2026.1812847
Husser, F., Arab, L., Drouin, S., Rafat, C., Mesnard, L., Montagne, S., Brochériou, I., Rouvier, P., François, H., & Mousseaux, C. (2026) · Kidney International Case Reports · doi:10.1016/j.kintcr.2026.100122
Renal transplantation in congenital heart diseases: A systematic review of outcomes and challenges
Magsi, N., Afaq, M., Ahsan, A. A., Farhan, K., Mehmood, F., Aslam, M., & Kumar, D. (2026) · Urologia Journal · doi:10.1177/03915603261486075
Metadata
- Authors
- Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyó, J., Neumayer, H.-H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., Block, A., Duan, T., Glicklich, A., Gujrathi, S., & Vincenti, F.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Medical College of Wisconsin (US)
- Hospital Clínic de Barcelona (ES)
- Charité – Universitätsmedizin Berlin (DE)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Emory University (US)
- Instituto Nacional de Cardiología (MX)
- University of California, San Francisco (US)
- Corresponding author
- Vanrenterghem, Yves
- Venue
- Transplantation
- Published
- 2011-05-15
- Volume
- 91
- Issue
- 9
- Pages
- 976-983
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1976465544
- Cited by
- 183
- References
- 67
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 8 · 2023: 6 · 2022: 10 · 2021: 10 · 2020: 5 · 2019: 11 · 2018: 8 · 2017: 10 · 2016: 11 · 2015: 15 · 2014: 24 · 2013: 13 · 2012: 24
- FWCI
- 16.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- belatacept, cyclosporine, kidney transplantation, cardiovascular risk, metabolic risk, blood pressure, serum lipids, non-HDL cholesterol, triglycerides, post-transplant diabetes mellitus, calcineurin inhibitors, immunosuppressive regimens, costimulation blockade
- MeSH terms
- Abatacept, Adult, Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Immunosuppressive Agents, Lipids, Male, Middle Aged, Risk Factors, Kidney Transplantation, Cyclosporine, Immunoconjugates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.